The pharmacokinetics of fosfestrol and diethylstilbestrol in chronic hemodialysis patients with prostate cancer

Abstract

Fosfestrol drip infusion therapy appeared to be safe as an endocrinotherapy for prostate cancer in chronic hemodialysis patients.

Assay of the synthetic estrogen fosfestrol in pharmaceutical formulations using capillary electrophoresis

“…Pharmacokinetic studies have shown that fosfestrol metabolites have a short half-life, supporting its suitability for long-term infusions in the clinic. It relieves the patients' urinary symptoms, such as poor flow, by shrinking the tumor [2].…”